Treating coronavirus patients with the antiviral drug remdesivir showed no "significant clinical benefits" in the first randomised trial of its kind, according to a review released on Wednesday. In a study among more than 200 COVID-19 patients in Wuhan, China, published in The Lancet, doctors found no positive effects of administering the drug compared with a control group of adults. The findings were released after US pharmaceutical giant Gilead, which makes remdesivir, said a separate large-scale trial with the drug had showed positive results. pg-pr/jxb